

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Beebe Medical Center c/o Radiology Dept. 2. 424 Savannah Road Lewes, DE 19958	In accordance with letter dated January 02, 2018.	4. Expiration Date: June 30, 2024
	3. License number: 07-17792-01 is amended in its entirety to read as follows:	5. Docket No.: 030-13331 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1000 millicuries total	C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
07-17792-01

Amendment No. 52

Docket or Reference Number
030-13331

- | | | | |
|--|--|--|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>D. Any byproduct material permitted in 10 CFR 35.400</p> | <p>7. Chemical and/or physical form</p> <p>D. Sealed Sources (Amersham/Medi-Physics, Inc., Model 6702; Bard Brachytherapy, Inc., Model STM1251; Best Medical International, Inc., Model 2301 Series; Eckert & Ziegler Bebig, Inc., Model 125.S06; IsoAid, LLC, Model IAI-125A; Medi-Physics, Inc. (d/b/a GE Healthcare), Model 6711; Theragenics Corporation, Model AGX100; Theragenics Corporations, Model I25.S06)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>D. 1000 millicuries total</p> | <p>9. Authorized use</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</p> |
|--|--|--|--|

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 424 Savannah Road, Lewes, Delaware.
- B. Licensed material listed in Subitem No. 6.B. and 6. D. may be used or stored at the licensee's facilities located at Beebe Health Campus, Bookhammer Outpatient Center, 18941 John J. Williams Highway (Route 24), Rehobeth Beach, Delaware.
11. The Radiation Safety Officer for this license is Lisa Marie Genovese, DMP.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

07-17792-01

Docket or Reference Number

030-13331

Amendment No. 52

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Material and Use

Frances Esposito, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Jeffrey McCann, M.D.

10 CFR 35.100, 10 CFR 35.200

Andrejs Strauss, M.D.

10 CFR 35.400

Ellen Bahtiaran, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Michael Ramjattansingh, M.D.

10 CFR 35.100, 10 CFR 35.200

Andrew Dahlke, M.D.

10 CFR 35.100, 10 CFR 35.200

Brian Costleigh, M.D.

10 CFR 35.300, 10 CFR 35.400

Georges Abdul-Karim Dahr, M.D.

10 CFR 35.200

Ramon Alberto Rosa, M.D.

10 CFR 35.200

Rajinder Prasad, M.D.

10 CFR 35.200

Dennis Michael Flamini, D.O.

10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide I-131

Jennifer Hung, M.D.

10 CFR 35.400

Mouhanad K. Freih, M. D.

10 CFR 35.100, 10 CFR 35.200

Barry S. Denenberg, M. D.

10 CFR 35.200

Kimberly Gardner, M. D.

10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
07-17792-01Docket or Reference Number
030-13331

Amendment No. 52

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated January 20, 2011, except shielding assessment [ML110200525]
 - B. Letter dated February 7, 2011 [ML110390314]
 - C. Facility diagrams received March 19, 2012 [ML120790362]
 - D. Application dated December 18, 2013 [ML14014A072]
 - E. Letter dated May 29, 2014 [ML14163A664]
 - F. Letter dated July 21, 2017 [ML17236A325]
 - G. Letter dated February 14, 2018

Date: February 22, 2018

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Farrah Gaskins
Region 1